Intelligence · Clinical pipeline
Approved programs Pipeline Programs
ClinicalTrials.gov programs marked approved or launched in registry data.
Quick answer
NovaPharmaNews tracks 1,839 approved programs pharmaceutical pipeline programs from ClinicalTrials.gov. ClinicalTrials.gov programs marked approved or launched in registry data.
Top sponsors
- Chinese Academy of 207 programs
- First People's Hospital 186 programs
- Takeda 154 programs
- United Therapeutics Europe 121 programs
- BRIGHT MINDS BIOSCIENCES 116 programs
- Disc Medicine 103 programs
- George Institute for 83 programs
- Hospital Authority 60 programs
- Regeneron UK 60 programs
- Sinovac Research and 47 programs
- Teva Pharma 39 programs
- Pacira Ireland 36 programs
Pipeline programs
-
AO-128
Takeda
Impaired Glucose Tolerance (IGT)
1 trial -
APHP 190183
Pari Pharma GmbH
Crohn’s disease
1 trial -
APHP180618
Pari Pharma GmbH
Asymptomatic Patients with frequent PVCs and normal LVEF
1 trial -
APHP200002
Pari Pharma GmbH
Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% premature atrial contractions (PAC) /24 hours or any atrial runs ≥ 20 PACs (but shorter than 30 seconds) on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3. Patients with any atrial runs ≥ 20 PACs but shorter than 30 seconds on a 15-21 days Holter ECG monitoring and CHA2DS2VASC score ≥ 3 may also be included in the Short-Run trial.
1 trial -
APHP200020
Pari Pharma GmbH
Pyelonephritis, Kidney Transplant recipients
1 trial -
APHP210085
Pari Pharma GmbH
EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).
1 trial -
APHP220806
Pari Pharma GmbH
Women who delivered by caesarean and have a moderate postpartum iron deficiency anaemia defined by 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL within 72h after delivery and a ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% (Measured after postoperative Hb level measurement)
1 trial -
APOKYN
SUPERNUS PHARMACEUTICALS, INC.
Parkinson's Disease
2 trials -
ARALAST Alpha1-Proteinase Inhibitor
Takeda
Alpha1-antitrypsin Deficiency
1 trial -
ARALAST NP
Takeda
Chronic Obstructive Pulmonary Disease
1 trial -
ARIPIPRAZOLE , RISPERIDONE
Disc Medicine
Autism spectrum disorder
1 trial -
ARMYDA-AMULET
Fondazione Telethon ETS
Patients with atrial fibrillation undergoing percutaneous left atrial appendage closure with the Amulet device
1 trial -
ATORVASTATIN, PLACEBO
Disc Medicine
Atherosclerosis
1 trial -
ATRA+Arsenic
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Promyelocytic Leukemia
1 trial -
AXS-05
Axsome Therapeutics
Major Depressive Disorder
3 trials -
AZD1222
AstraZeneca
COVID-19, SARS-CoV-2
1 trial -
Abemaciclib
Eli Lilly and Company
Metastatic Breast Cancer
1 trial -
Abemaciclib
Eli Lilly and Company
Breast Neoplasms
1 trial -
Ablation
Rhythm Pharmaceuticals Netherlands B.V.
Atrial Fibrillation
1 trial -
Academic Detailing
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
Acarbose 100 MG
RenJi Hospital
PCOS
1 trial -
Access Arm
Rhythm Pharmaceuticals Netherlands B.V.
Heart Failure
1 trial -
Acetazolamide
United Therapeutics Europe Ltd
Hypobaric Hypoxia
1 trial -
Acetylsalicylzuur Aurobindo cardio for ST elevation myocardial infarct…
Disc Medicine
ST elevation myocardial infarction (STEMI)
1 trial -
Active Procedure
United Therapeutics Europe Ltd
Low Back Pain
1 trial -
Adalimumab
Takeda
Crohn's Disease
1 trial -
Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]
AVENUE THERAPEUTICS, INC.
Acne Vulgaris
1 trial -
Adderall
BRIGHT MINDS BIOSCIENCES INC.
Attention Deficit Disorder With Hyperactivity
1 trial -
Adefovir
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis B, Chronic
1 trial -
AdreView
Aspire Biopharma Holdings
Heart Failure
1 trial -
Adult group in immunogenicity and safety study of combined immunization
Sinovac Research and Development Co.,
COVID-19
1 trial -
Advair Diskus100/50 µg
Teva Pharma GmbH
Asthma
1 trial -
Aerosolized 13 cis retinoic acid plus Vitamin D
The First People's Hospital of Lianyungang
Post COVID-19 Anosmia (Loss of Smell)
1 trial -
Afatinib
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
1 trial -
Aflibercept
Regeneron UK Limited
Fibrovascular Pigment Epithelial Detachment
1 trial -
Aflibercept
Regeneron UK Limited
Exudative Macular Degeneration
1 trial -
Aflibercept
Regeneron UK Limited
Age Related Macular Degeneration
1 trial -
Aflibercept
Regeneron UK Limited
Diabetic Retinopathy
2 trials -
Aflibercept
Regeneron UK Limited
Submacular Vascularized Pigment Epithelial Detachments
1 trial -
Aflibercept
Regeneron UK Limited
Diabetic Macular Edema
2 trials -
Aflibercept
Regeneron UK Limited
Retinal Vein Occlusion
2 trials -
Aflibercept (2.0 mg)
Regeneron UK Limited
Macular Edema With Central Retinal Vein Occlusions
1 trial -
Aflibercept (BAY86-5321, Eylea)
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Regeneron UK Limited
Diabetic Macular Edema (DME)
1 trial -
Aflibercept Injection
Regeneron UK Limited
Diabetic Retinopathy
2 trials -
Aflibercept Ophthalmic
Regeneron UK Limited
Wet Macular Degeneration
1 trial -
AirDuo Digihaler
Teva Pharma GmbH
Asthma
1 trial -
Albendazole
United Therapeutics Europe Ltd
Ascariasis
1 trial
Frequently asked questions
How many Approved programs pipeline programs are in the directory?
1,839 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.